8legs: Astrazeneca

Your Followed Topics

#1 out of 2

AstraZeneca pledged £300 million for UK sites, reversing a pause on major investments.
Funds will unfreeze £200m in Cambridge and add £100m to Macclesfield’s site expansion.
Keir Starmer announced the plan in the House of Commons, calling it a vote of confidence in UK science.
Cambridge office will be completed near AstraZeneca’s headquarters and named after Rosalind Franklin.
AstraZeneca’s new Macclesfield lab aims to use digital tools to speed drug development.
The UK-US pricing deal helped enable the investment and aims to safeguard jobs.
AstraZeneca employs about 10,000 people in the UK, with significant numbers in Cambridge and Macclesfield.
Industry confidence in UK life sciences grows alongside the new investment plan.
Other firms, including Boehringer Ingelheim and GSK, are expanding UK presence amid the momentum.
Analysts see AstraZeneca's move as strategically reinforcing the UK life sciences sector.

Vote 0

#2 out of 2

AstraZeneca reported Q1 2026 revenue of $15.29 billion, with product sales at $14.39 billion.
The company reaffirmed its 2026 guidance despite the late-stage trial delays.
Two Datroway late-stage lung cancer trials were delayed to 2027, affecting near-term pipeline timing.
AZN bought an exclusive global license for PTX-299, paying $25 million upfront with potential milestones and royalties.
The PTX-299 deal includes potential milestones and royalties possibly exceeding $500 million.
Analysts largely favor AstraZeneca with a mix of buy and strong buy ratings; the 12‑month target sits above the last close.
TradingView notes AZN will report earnings in the European results round, with no figures provided yet.
AZN's oncology segment remains a major revenue contributor, comprising about 44% of total revenue.
AZN's core operating profit rose about 12% in the first quarter.
The AZN-PTX-299 deal could become a significant growth driver if milestones and royalties materialize.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.